- Home
- RVNC vs BX Comparison
RVNC vs BX Comparison
Compare RVNC & BX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVNC
- BX
- Stock Information
- Founded
- RVNC 1999
- BX 1985
- Country
- RVNC United States
- BX United States
- Employees
- RVNC N/A
- BX N/A
- Industry
- RVNC Biotechnology: Pharmaceutical Preparations
- BX Investment Managers
- Sector
- RVNC Health Care
- BX Finance
- Exchange
- RVNC Nasdaq
- BX Nasdaq
- Market Cap
- RVNC 320.5M
- BX 144.6B
- IPO Year
- RVNC 2014
- BX 2007
- Fundamental
- Price
- RVNC $3.09
- BX $170.84
- Analyst Decision
- RVNC Hold
- BX Buy
- Analyst Count
- RVNC 9
- BX 20
- Target Price
- RVNC $8.45
- BX $162.72
- AVG Volume (30 Days)
- RVNC 3.6M
- BX 3.9M
- Earning Date
- RVNC 11-07-2024
- BX 01-23-2025
- Dividend Yield
- RVNC N/A
- BX 2.01%
- EPS Growth
- RVNC N/A
- BX 22.28
- EPS
- RVNC N/A
- BX 2.90
- Revenue
- RVNC $256,945,000.00
- BX $11,138,276,000.00
- Revenue This Year
- RVNC $11.28
- BX $51.75
- Revenue Next Year
- RVNC $27.21
- BX $29.82
- P/E Ratio
- RVNC N/A
- BX $58.98
- Revenue Growth
- RVNC 25.82
- BX 35.11
- 52 Week Low
- RVNC $2.30
- BX $114.88
- 52 Week High
- RVNC $9.75
- BX $200.96
- Technical
- Relative Strength Index (RSI)
- RVNC 33.47
- BX 35.77
- Support Level
- RVNC $3.06
- BX $187.74
- Resistance Level
- RVNC $3.09
- BX $192.17
- Average True Range (ATR)
- RVNC 0.11
- BX 4.84
- MACD
- RVNC 0.02
- BX -3.04
- Stochastic Oscillator
- RVNC 6.90
- BX 17.13
About RVNC Revance Therapeutics Inc.
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.
About BX Blackstone Inc.
Blackstone is the world's largest alternative-asset manager with $1.108 trillion in total asset under management, including $820.5 billion in fee-earning assets under management, at the end of September 2024. The company has four core business segments: private equity (25% of fee-earning AUM and 30% of base management fees), real estate (35% and 39%), credit and insurance (31% and 24%), and multi-asset investing (9% and 7%). While the firm primarily serves institutional investors (87% of AUM), it also caters to clients in the high-net-worth channel (13%). Blackstone operates through 25 offices in the Americas (8), Europe and the Middle East (9), and the Asia-Pacific region (8).